Honor Recognizes Companies Advancing Innovative Solutions to Improve Women’s Health and Safety in Emerging Markets Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced that …
Trending at Lumira Ventures
LQT Therapeutics Announces Award by the European Joint Program for Rare Diseases for SGK1 inhibition as a novel therapeutic approach in Long QT Syndrome
Closing the gap between industry and academia to place patients directly at the center of research efforts. LQT Therapeutics, a privately-held biopharmaceutical company advancing novel SGK1 kinase therapeutics, today announced that the project, “SILENCE-LQTS: SGK1 inhibition as a novel therapeutic …
Lumira Ventures Announces Promotion of Lu Han, Ph.D. to Partner and Team Expansion
TORONTO, January 6, 2022 – Lumira Ventures, a leading North American healthcare venture capital firm, today announced the promotion of Dr. Lu Han, Ph.D., to Partner and the appointments of Dr. Suman Rao, Ph.D. as an Associate and Dr. Ai …
Endotronix Announces FDA Approval for PROACTIVE-HF Pivotal Trial Design Change to Single-Arm Study
Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the U.S. Food and Drug Administration (FDA) has granted approval for an amendment to the company’s PROACTIVE-HF study, a pivotal …
Specific Biologics Closes Seed Financing with Industry Leaders Lumira Ventures and adMare BioInnovations
Specific Biologics Inc. (“Specific”) today announced that it has closed its first institutional financing, led by Lumira Ventures and adMare BioInnovations which have recently established an innovative partnership to build Canadian life sciences companies. Gene editing holds the potential to …
Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection
Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection. A single cohort in the ongoing Antios …
OpSens Announces 510(K) Submission to U.S FDA for New Guidewire for the TAVR Procedure
OpSens Inc. (“OpSens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that it has filed a 510(k) submission with the U.S. Food & Drug Administration (“FDA”) for regulatory clearance of its …
Lumira Co-Leads OncoMyx $50 Million Series B to Advance a Novel Immuno-Oncology Platform that Delivers Multiple Cancer-Killing Payloads
OncoMyx Therapeutics, a privately-held immuno-oncology platform company, today announced the closing of a $50 million Series B financing, co-led by Lumira Ventures and B Capital Group with participation from LYZZ Capital and all Series A investors: Boehringer Ingelheim Venture Fund, …
Suman Rao Speaks as an Investor Judge at the 2021 Venture Summit Virtual Connect
Join Lumira Ventures, Associate, Suman Rao for the 2021 Venture Summit Virtual Connect. The summit brings together leading innovators and investors across various fields including life science / healthcare to connect and network virtually. Suman has been invited to provide …
Canada’s Health Care Innovation Status and What Must Happen to Boost Our System to the Next Level: Peter van der Velden Shares his Thoughts on the ReBoot Health Podcast
As a seasoned veteran in the Canadian health ecosystem, Lumira Ventures Managing General Partner, Peter van der Velden shares his perspective on the critical aspects that fuel the system in a captivating discussion with Amol Deshpande on the Reboot Health …
Suman Speaks on the Venture Capital and Investment Banking for Life Sciences Panel
Join Lumira Ventures, Associate, Suman Rao for a panel discussion on the role of venture capital groups and investment banks in getting scientific research funded and out to the public. Suman alongside the other panelist speakers will discuss how venture …
Deka Biosciences Raises $20 Million in Series A Financing
Maryland-based biotech company Deka Biosciences (“Deka”) today announced that it has successfully closed a USD 20 Million Series A financing with a syndicate of life science investors led by Leaps by Bayer, the impact investment arm of Bayer AG, and new investor …
Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)
Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), and IRBM, a drug discovery and early development research institute and global contract research organization, announced today they entered into …
G1 Therapeutics Announced Immune Analysis from Phase 2 Triple Negative Breast Cancer Trial Demonstrates Trilaciclib Enhanced Patients’ T Cell Immune Function When Administered Prior to Chemotherapy
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results from an immunologic analysis of Phase 2 study data showing that trilaciclib enhances both CD4 and CD8 T cell function in certain patients with metastatic triple negative breast cancer (mTNBC) …
Nikhil Thatte Speaks at the BioTEC Biotechnology and Bioengineering Conference
Join Lumira Ventures, Principle, Nikhil Thatte for BioTEC’s Biotechnology and Bioengineering Conference November 13th , 2021 at 11:00 AM EST and November 14th, 2021 at 7:30PM EST. A weekend filled with insightful talks, exciting exhibitions, and innovative ideas as they …